ResearchMoz.us

ResearchMoz is the one stop online destination to find and buy market research reports and Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Showing posts with label GBI's Research report. Show all posts
Showing posts with label GBI's Research report. Show all posts

Thursday, 12 December 2013

Monoclonal Antibodies Market in Colorectal Cancer to 2019

ResearchMoz.us include new market research report"Monoclonal Antibodies Market in
Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth " to its huge collection of research reports.

GBI Research, has released the pharma report - “Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a number of oncology indications.


While compelling late-stage candidates are absent from the current pipeline, the anticipated rise in total prevalence of colorectal cancer in the top eight markets may inspire further investment. Pricing patterns for mAbs are highly favorable in the US, the largest market for colorectal cancer, and patent expirations are not expected to have a substantial effect on any of the featured markets. As a result of this, GBI Research believes the global market has the potential to grow to a value of $5.5 billion by 2019.

Scope

A brief introduction to colorectal cancer, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms.
In-depth analysis of the three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy.
A comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets.

Browse All GBI Market Research Report @ http://www.researchmoz.us/publisher/gbi-research-2.html

Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type, in addition to an in-depth analysis of clinical trial primary endpoints.
Multi-scenario forecast data of the market to 2019, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets.
Discussion of the drivers and barriers for market growth.
In-depth analysis of all licensing and co-development deals that have occurred in the colorectal cancer market since 2006.

Reasons to Buy

Understand the role of mAbs in the treatment of colorectal cancer and their relation to chemotherapies and targeted small molecule therapies.
Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
Observe the trends in clinical trial duration and size amongst clinical phases and molecule types. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for colorectal cancer therapeutics.
Observe the shift in clinical trial endpoints throughout clinical phases of development, and use this data to potentially influence any future developmental programs.
Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the colorectal cancer mAbs market.

All Latest Market Research Report @ http://www.researchmoz.us/latest-report.html

For More Information Kindly Contact:
Email: sales@researchmoz.us 

Monday, 25 November 2013

Cardiovascular Diseases Therapeutics Market in Asia-Pacific to 2019 | Researchmoz.us



ResearchMoz.us include new market research report" Cardiovascular Diseases Therapeutics Market in Asia-Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use" to its huge collection of research reports.

GBI Research has released its pharmaceutical research, "Cardiovascular Diseases Therapeutics Market in Asia-Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use", which provides insights into three cardiovascular therapeutic indications in in Asia-Pacific (APAC) markets of India, China, Japan and Australia. 


The report provides an in-depth analysis of the cardiovascular therapeutic indications, namely heart failure, myocardial infarction (MI), acute coronary syndrome (ACS). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three cardiovascular indications.

Scope

Disease overview and treatment usage patterns
Market size and forecast for heart failure, MI and ACS in APAC market from 2012 to 2019
Major marketed products for the indications types covered
In-depth pipeline analysis for heart failure, MI and ACS
Key drivers and restraints that have had and are expected to have a significant impact upon the market
Key licensing and co-development agreements in the cardiovascular market

Browse All Upcoming Market Research Report @ http://www.researchmoz.us/upcoming-report.html

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

Align your product portfolio to the markets with high growth potential
Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the cardiovascular market
Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Browse reports in Pharmaceutical Market @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Related Report






About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.


Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

Thursday, 12 September 2013

Latest Research On Telemedicine and M-Health Convergence Report Available At Researchmoz

Researchmoz presents this most up-to-date research on"Telemedicine and M-Health Convergence: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2019".The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

Researchmoz presents this most up-to-date research on"Telemedicine and M-Health Convergence: Market Shares, Strategies, and Forecasts, Worldwide, 2013 to 2019".The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.


Research announces that it has published a new study Telemedicine and M-Health Market Convergence Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. The 2013 study has 879 pages, 299 tables and figures. Worldwide markets are poised to achieve significant growth as the telemedicine systems merge with the smart phone systems of engagement to provide a way to improve clinical care delivery to patients with chronic disease, decreasing hospitalizations and visits to the emergency room. 

There is a convergence of telemedicine and m-health as the patients become more responsible for their own care delivery and their own health Clinical telemedicine services converge with m-health systems of engagement to lower cost of care and improve quality of care. Tele-medicine and M-Health Market Convergence driving forces relate to an overall trend toward ordinary people taking more responsibility for their own health. This trend has been more prevalent for women in the past 100 years than for men because women used to die very young and they had to learn how to keep themselves healthy. Women have been able to reverse this trend of dying young and to live longer than men in the past 40 years, illustrating that paying attention to health is important.

Healthcare patient, physician, and facility decision support markets are forecast based n the broad availability of smartphones combined with the IBM Watson technology that Watson offers Interactive Care Insights for Oncology. The cognitive systems use insights gleaned from the deep experience of Memorial Sloan-Kettering clinicians. Watson is positioned to permit clinicians to provide individualized treatment.

View All Healthcare Related Reports At : http://www.researchmoz.us/healthcare-market-reports-56.html

More options are based on patient medical information. IBM Watson in combination with Memorial Sloan-Kettering Cancer Center has information that represents the synthesis of a vast array of updated and vetted treatment. It is able to compute individual treatment guidelines. This represents a revolution in cancer treatment care and presages a major revolution in all healthcare treatment and diagnosis.

Because Watson is able to leverage published research it can stay more current than any clinician or group of clinicians can. Watson-is a cognitive computing system. The aim of Watson is to streamline the healthcare delivery process. Watson supports the healthcare decision making process. The system has the ability to ensure evidence-based care is provided.

Both tele-medicine and m-health contribute to healthcare delivery in the home. M-health will surely be delivered over the smart phone. Tele-medicine is evolving toward smart phone device delivery as well.

The cost of tele-medicine for the US veterans administration is $1,600 per patient per annum. This is substantially less than other NIC programs and nursing home care which can easily run to $100,000 per annum. VHA's experience is that an enterprise-wide home tele-medicine implementation is an appropriate and cost-effective way of managing chronic care patients in both urban and rural settings.

Chronic disease conditions are best treated early on when there is a change in patient condition and an early intervention can make a difference. It is even better to treat them in a wellness treatment environment before there are indications of chronic disease, before symptoms develop, by addressing lifestyle issues early on.

Left to their own judgments, some patients typically are apt to make terrible decisions relating to their personal health either because of ignorance, genetic inheritance, or because of lifestyle habit. The ability to accurately access patient condition via a combination of advanced testing and telemonitoring creates the opportunity to intervene when what is called for clinically can make a difference, and permits provision for education regarding healthy living in a way that is likely to create compliance with clinician recommendations.

Home telemonitoring programs need to use advanced technology. Effective monitors support patient education. They support timely clinician intervention based on real vital signs data gathered on a daily basis. Health care for patients with congestive heart failure has been shown to be successful in reducing hospitalizations and trips to the emergency department, making these critical measures unnecessary in many cases.

Home patient monitoring means two things: the imminent rise of the expert patient whom the health authorities anticipate would self-manage his long-term medical conditions and the prominence of mobile devices as the go-between for clinicians and patients.

Telemedicine markets are emerging software markets. The consumer tablet computers are poised to become ubiquitous and inexpensive. As this happens telemedicine is becoming a fee for services much as a cell phone. The software runs on industry standard tablet computing devices. Clinicians gather patients information on a daily basis and provide consultation and intervention as needed for chronic conditions.

Telemedicine now delivered on proprietary devices is becoming obsolete. The Honeywell / Samsung strategic alliance represents the model that works. Telemedicine market analysis indicates that the price points are way below device costs and that companies are seeking to gain market share by working with clients.

Telemedicine device and software companies recognize that their revenue stream will come from services delivery. Just as cell phones are paid for in conjunctions with the services contracts, so also the telemedicine applications will be paid by insurance. In some cases the insurance companies recognize that their long term costs are lower by delivering clinical intervention to try to impact lifestyle for patients with chronic disease conditions.

The telemedicine in the home is cheaper than the consequent emergency room visits and hospitalizations that occur if chronic conditions are ignored. There is a certain inevitability related to chronic disease condition care delivery. People that take care of themselves tend to stay healthy. People that are not attentive to protecting their health tend to have medical conditions that contribute to deteriorating health and benefit from early intervention when it is delivered in a manner to which the person can relate.

Telemedicine is, at its core, a way to extend clinical services to make them part of lifestyle consultation. . It provides a way to initiate two way communications with a patient, forever changing the doctor - patient relationship to a collaborative one. It means that physicians need to build collaboration skills or delegate those to their nurses which they have always done, but this time in a more effective manner, on that is supported by technology.

Telemedicine systems come from IBM, Intel, Honeywell, Vitarian, and Bosch Diagnostic Support Expert Systems. Tablets are poised to change telemedicine as are telepresence systems from Logitech among others. Clinical diagnosis is being impacted by the decision support systems. Clinical decision support systems (CDSS) have been a key aspect of telemedicine. Bosch offers the ability to track and update on a daily basis, questions that are able to address actual situations that patients face.

Diagnostic support expert systems promise to revolutionize healthcare. The mandated electronic health record (EHR) systems in all healthcare facilities, is a key enabler of diagnostic support expert systems. The objectives are to promote better and cheaper healthcare using diagnostic support based on the patient data collected from the telemedicine systems. With the large amount of new data collected by the newly installed EHR systems, computers like the Watson will be able to find optimal answers to clinical questions much more efficiently than the human mind.

Two major categories are diagnostic support tools and treatment support tools. Chronic conditions requires continuous diagnostic support because a continuous flow of information on patient change in conditions helps physicians make a better diagnosis based on the patient symptoms, medications, and medical records.

Treatment support helps clinicians stay compliant with known treatment guidelines such as avoiding known drug interactions, dispensing the right medication to the right patients, and staying on schedule with response to changes in patient condition.

According to Susan Eustis, lead author of the WinterGreen Research team that prepared the telemedicine market research study, "Differential diagnostic tools support differential telemedical treatment. The decision process take into account clinical findings form the home monitoring devices and from symptoms verbally communicated in a clinical services implementation."

She continued, "Care delivery is enhanced by having clinicians be responsive to changes in patient condition that we know will lead to further patient deterioration if not treated immediately. A core part of responsible healthcare delivery is to use technology for healthcare reform. There is a focus on how to deliver care differently using telemedicine. No matter who pays for it, the use of telemedicine is anticipated to reduce the overall costs of healthcare delivery. Innovation is key to achieving improvements."

For long-term success, telehealth solutions require sustainable financing models. Investments in telehealth technologies foster sustainability by enabling productivity and efficiency gains and other improvements that can more than justify investment costs.

Government and local authorities have long recognized the potential of telehealth technology as a tool for delivering health and social care services. This is an increasing imperative given the increasing age demographic and the backdrop of static or reducing funding. Telehealth initiatives must demonstrate credibility and viability beyond the pilot and trial programs in order to achieve the goal of increased capability through technology.

Device installer partners define benefits in terms of increased sales and consultancy. A sustaining finance model is an essential aspect of telehealth. Telemedicine is analogous to the telecommunications industry where a large upfront investment is required an, usage models and complementary technologies must emerge and finally they must be integrated into existing healthcare service delivery paradigms.

Workflows are required to integrate the telehealth components into the existing solutions. This is possibly the area of greatest challenge. Upfront costs are high. Once the telehealth solution has been implemented initiatives are cost effective.

Since insurance companies have the responsibility for taking care of all people, not just the healthy ones and the health conscious people, they benefit from encouraging the use of telemedicine. The US veterans' administration recognizes this reality and has in place extensive telemedicine programs. While some hospitals benefit from an increase in hospitalizations, insurers do not.

There is a services component to the business that makes it attractive to sell the devices below cost. The tablet market revolutionizes telemedicine.

Once FDA approved software runs on a tablet, people with an existing unit can download software and be equipped with a way to interact with the clinical service that performs monitoring. Long term, the services will be a very attractive part of telemonitoring.

Telemedicine dedicated device and software markets at $843 million in 2012 are anticipated to reach $2.9 billion by 2019. M-Health markets related to telemedicine at $1.4 billion are anticipated to reach $1.5 trillion by 2019 due to the use of 7 billion smart phones and half that many connected tablet devices all over the world.

Contact Us: 
M/s Sheela 
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us 
www.linkedin.com/company/researchmoz

Multiple Sclerosis Therapeutics to 2019

Multiple Sclerosis Therapeutics Market report is designed for clients needing a quality in-depth understanding of the Multiple Sclerosis Therapeutics Market report. These reports provide a much more granular and detailed data set than our competitors. All data have been researched, brand upwards, by an experienced ''on-the-ground'' industry analyst who conducts face-to-face interviews with key producers, leading companies in allied industries, distributors and retailers.


GBI Research, the leading business intelligence provider, has released its latest research, “Multiple Sclerosis Therapeutics to 2019 Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth”. Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake. As a result of this, as well as an overall increase in the treated population, GBI Research believes the global market has the potential to grow to a value of $17.9 billion by 2019.

Scope

A brief introduction to MS, including the disease’s history, pathogenesis, risk factors and diagnosis.In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.Comprehensive review of the pipeline for MS therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.Additional analysis of pipeline drug clinical trials by phase, molecule type, trial size and trial duration.Multi-scenario forecast model of the market, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology.Discussion of the drivers and barriers for market growth or decay.

Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

Reasons to buy

Understand the different levels of MS therapies, from early-stage/mild MS to late-stage/aggressive MS.Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for multiple sclerosis therapeutics.Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs. Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the multiple sclerosis therapeutics market.

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Disease Overview 8

2.2 Epidemiology 8

2.3 Symptoms 9

2.4 Etiology 9

2.5 Pathophysiology 10

2.5.1 Blood Brain Barrier Degradation 10

2.5.2 Cellular Infiltration of the Central Nervous System 10

2.6 Co-morbidities/Complications 11

2.7 Diagnosis 12

2.7.1 McDonald Criteria 12

2.7.2 Physical Examination 13

2.7.3 MRI Scans 13

2.7.4 Lumbar Puncture 13

2.7.5 Other Diagnostic Tests 13

2.8 Prognosis 14

2.9 Treatment Efficacy 15

2.10 Treatment Options 15

Browse All Countrywise Report@ http://www.researchmoz.us/country.html

List of Figures

Figure 1: Treatment Algorithm, Global, Multiple Sclerosis, 2013 18
Figure 2: Multiple Sclerosis, Marketed Products Heat Map 27
Figure 3: Overall Pipeline for Multiple Sclerosis 30
Figure 4: Routes of Administration in the Pipeline 31
Figure 5: Molecular Targets of Pipeline Molecules 32
Figure 6: Molecular Targets in MS Pipeline by Phase of Development 33
Figure 7: Failure Rate of MS Clinical Trials, 2006–2013 35
Figure 8: Reasons for Clinical Trial Failure, 2006–2013 36
Figure 9: Clinical Trial Size by Product and Phase, 2006–2013 37
Figure 10: Clinical Trial Duration by Phase and Molecule Type, 2006–2013 39
Figure 11: Multiple Sclerosis, Pipeline Product Heat Map 45
Figure 12: Multiple Sclerosis, Marketed Product Heat Map, 2012–2019 46
Figure 13: Multiple Sclerosis Market, Global, Patient Volumes (‘000) and Market Size ($bn), 2012–2019 49

####

Related Report

1) Narcolepsy Global Clinical Trials Review, H2, 2013

Narcolepsy Global Clinical Trials Review,(http://www.researchmoz.us/narcolepsy-global-clinical-trials-review-h2-2013-report.html) H2, 2013" provides data on the Narcolepsy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Narcolepsy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Narcolepsy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

2) Bacteriuria Global Clinical Trials Review, H2, 2013

Bacteriuria Global Clinical Trials Review,(http://www.researchmoz.us/bacteriuria-global-clinical-trials-review-h2-2013-report.html) H2, 2013" provides data on the Bacteriuria clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bacteriuria. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bacteriuria. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

3) Osteoporosis Global Clinical Trials Review, H2, 2013

Osteoporosis Global Clinical Trials Review,(http://www.researchmoz.us/osteoporosis-global-clinical-trials-review-h2-2013-report.html) H2, 2013" provides data on the Osteoporosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Osteoporosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Osteoporosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.


For More Information Kindly Contact:

Thursday, 1 August 2013

Pain Management Therapeutics Market 2019 Forecast

ResearchMoz.us include new market research report"Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline " to its huge collection of research reports.

“Pain Management Therapeutics Market to 2019 Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline“ provides insights and analysis into the market. Pain is a widespread problem across the world. More than 25% of the total population suffers from some clinically significant pain in a year. Since pain considerably affects day-to-day activities in life, its management presents a considerable challenge for physicians. Inadequate pain control remains a major problem across the world. There is an urgent and unmet need to manage these pain-related problems accurately. Currently, the management of pain is not efficient due to low diagnosis and prescription rates. In many cases, such as cancer pain, 50% of the people taking medicines are not satisfied with the results. This is primarily due to the absence of a perfect pain management solution. Pain management can be most effective only when the underlying disease conditions are cured. However, there is no treatment that offers absolute relief for the indications covered in this report. The medications given for these indications are more for modifying the disease symptoms than offering complete relief from pain. The combination of under-managed pain, low awareness, and fear of addiction to some classes of pain medication is preventing people suffering pain from seeking treatment 100% of the time.

Complete Report With TOC @ http://www.researchmoz.us/pain-management-therapeutics-market-to-2019-impact-of-patent-expiries-offset-by-demand-for-neuropathic-and-rheumatoid-pain-medications-and-strong-pipeline-report.html

Scope

Overview of the pain management market by analyzing the revenue, Annual Cost of Therapy (ACT) and treatment usage pattern across the top seven markets, which are the US, the UK, France, Germany, Spain, Italy and Japan.
Therapeutic landscape of the pain management therapeutics market and includes detailed market sizing and analysis of the trends in eight indications, which are fibromyalgia, neuropathic pain, cancer pain, Osteoarthritis (OA) pain, Rheumatoid Arthritis (RA) pain, migraine, Low Back Pain (LBP) and post-operative pain.
Geographical landscape of the pain management therapeutics market in the top seven markets, which are the US, the UK, France, Germany, Spain, Italy and Japan.
Detailed pipeline analysis of the pain management market (as of April 2013). The section also contains detailed analyses of the most promising pipeline molecules.
Profiles of the top companies operating in the pain management therapeutics market.
List of strategic consolidations, such as M&A deals, licensing agreements and partnership deals that took place in the global pain management therapeutics market between 2007 and 2013.

Browse All GBI Research Market Research Reports @ http://www.researchmoz.us/publisher/gbi-research-2.html

Reasons to buy

Align your product portfolio to the markets with high growth potential.
Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
Devise a more tailored country strategy through the understanding of key drivers and barriers of the region’s pain management therapeutics market.
Develop key strategic initiatives by understanding the key focus areas and top selling pain management therapeutics molecules of leading companies.
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:
Email: sales@researchmoz.us